Literature DB >> 22025548

B7-h1 expressed by activated CD8 T cells is essential for their survival.

Vesna Pulko1, Kimberley J Harris, Xin Liu, Rachel M Gibbons, Susan M Harrington, Christopher J Krco, Eugene D Kwon, Haidong Dong.   

Abstract

An immunoinhibitory role of B7 homologue 1 (B7-H1) expressed by non-T cells has been established; however, the function of B7-H1 expressed by T cells is not clear. Peak expression of B7-H1 on Ag-primed CD8 T cells was observed during the contraction phase of an immune response. Unexpectedly, B7-H1 blockade at this stage reduced the numbers of effector CD8 T cells, suggesting B7-H1 blocking Ab may disturb an unknown function of B7-H1 expressed by CD8 T cells. To exclusively examine the role of B7-H1 expressed by T cells, we introduced B7-H1 deficiency into TCR transgenic (OT-1) mice. Naive B7-H1-deficient CD8 T cells proliferated normally following Ag stimulation; however, once activated, they underwent more robust contraction in vivo and more apoptosis in vitro. In addition, B7-H1-deficient CD8 T cells were more sensitive to Ca-dependent and Fas ligand-dependent killing by cytotoxic T lymphocytes. Activation-induced Bcl-x(L) expression was lower in activated B7-H1-deficient CD8 T cells, whereas Bcl-2 and Bim expression were comparable to the wild type. Transfer of effector B7-H1-deficient CD8 T cells failed to suppress tumor growth in vivo. Thus, upregulation of B7-H1 on primed T cells helps effector T cells survive the contraction phase and consequently generate optimal protective immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025548      PMCID: PMC3221917          DOI: 10.4049/jimmunol.1003976

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway.

Authors:  Nizar Chetoui; Marc Boisvert; Steve Gendron; Fawzi Aoudjit
Journal:  Immunology       Date:  2010-05-04       Impact factor: 7.397

3.  Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.

Authors:  Shari Pilon-Thomas; Amy Mackay; Nasreen Vohra; James J Mulé
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

4.  B7-H1 (programmed cell death ligand 1) is required for the development of multifunctional Th1 cells and immunity to primary, but not secondary, Salmonella infection.

Authors:  Seung-Joo Lee; Hope O'Donnell; Stephen J McSorley
Journal:  J Immunol       Date:  2010-07-16       Impact factor: 5.422

Review 5.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

6.  TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.

Authors:  Vesna Pulko; Xin Liu; Christopher J Krco; Kimberley J Harris; Xavier Frigola; Eugene D Kwon; Haidong Dong
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

7.  B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses.

Authors:  Christian Wahl; Petra Bochtler; Lieping Chen; Reinhold Schirmbeck; Jörg Reimann
Journal:  Gastroenterology       Date:  2008-06-04       Impact factor: 22.682

8.  Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection.

Authors:  Su-Kil Seo; Hye-Young Jeong; Sae-Gwang Park; Soo-Woong Lee; Il-Whan Choi; Lieping Chen; Inhak Choi
Journal:  Immunology       Date:  2007-10-25       Impact factor: 7.397

9.  B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis.

Authors:  Sonja Ortler; Christoph Leder; Michel Mittelbronn; Alla L Zozulya; Percy A Knolle; Lieping Chen; Antje Kroner; Heinz Wiendl
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

10.  PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes.

Authors:  Jared H Rowe; Tanner M Johanns; James M Ertelt; Sing Sing Way
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

View more
  41 in total

1.  Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes.

Authors:  Ryoyo Ikebuchi; Satoru Konnai; Tomohiro Okagawa; Kazumasa Yokoyama; Chie Nakajima; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

2.  Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.

Authors:  Lei Zhang; John S Yu
Journal:  J Neurooncol       Date:  2019-05-31       Impact factor: 4.130

3.  Translation control of the immune checkpoint in cancer and its therapeutic targeting.

Authors:  Yichen Xu; Mauro Poggio; Hyun Yong Jin; Zhen Shi; Craig M Forester; Ying Wang; Craig R Stumpf; Lingru Xue; Emily Devericks; Lomon So; Hao G Nguyen; Alice Griselin; John D Gordan; Sarah E Umetsu; Siegfried H Reich; Stephen T Worland; Saurabh Asthana; Maria Barna; Kevin R Webster; John T Cunningham; Davide Ruggero
Journal:  Nat Med       Date:  2019-01-14       Impact factor: 53.440

4.  Combination rhIL-15 and Anti-PD-L1 (Avelumab) Enhances HIVGag-Specific CD8 T-Cell Function.

Authors:  Bruktawit A Goshu; Hui Chen; Maha Moussa; Jie Cheng; Marta Catalfamo
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

5.  GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Authors:  Tessa Gargett; Wenbo Yu; Gianpietro Dotti; Eric S Yvon; Susan N Christo; John D Hayball; Ian D Lewis; Malcolm K Brenner; Michael P Brown
Journal:  Mol Ther       Date:  2016-03-29       Impact factor: 11.454

6.  CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Authors:  Yiyi Yan; Siyu Cao; Xin Liu; Susan M Harrington; Wendy E Bindeman; Alex A Adjei; Jin Sung Jang; Jin Jen; Ying Li; Pritha Chanana; Aaron S Mansfield; Sean S Park; Svetomir N Markovic; Roxana S Dronca; Haidong Dong
Journal:  JCI Insight       Date:  2018-04-19

7.  Innate IFN-γ is essential for programmed death ligand-1-mediated T cell stimulation following Listeria monocytogenes infection.

Authors:  Jared H Rowe; James M Ertelt; Sing Sing Way
Journal:  J Immunol       Date:  2012-06-18       Impact factor: 5.422

8.  PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.

Authors:  Brian Diskin; Salma Adam; Marcelo F Cassini; Gustavo Sanchez; Miguel Liria; Berk Aykut; Chandan Buttar; Eric Li; Belen Sundberg; Ruben D Salas; Ruonan Chen; Junjie Wang; Mirhee Kim; Mohammad Saad Farooq; Susanna Nguy; Carmine Fedele; Kwan Ho Tang; Ting Chen; Wei Wang; Mautin Hundeyin; Juan A Kochen Rossi; Emma Kurz; Muhammad Israr Ul Haq; Jason Karlen; Emma Kruger; Zennur Sekendiz; Dongling Wu; Sorin A A Shadaloey; Gillian Baptiste; Gregor Werba; Shanmugapriya Selvaraj; Cynthia Loomis; Kwok-Kin Wong; Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-03-09       Impact factor: 25.606

9.  Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.

Authors:  Lavakumar Karyampudi; Purushottam Lamichhane; Adam D Scheid; Kimberly R Kalli; Barath Shreeder; James W Krempski; Marshall D Behrens; Keith L Knutson
Journal:  Cancer Res       Date:  2014-04-11       Impact factor: 12.701

10.  Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.

Authors:  Asim Saha; Roddy S O'Connor; Govindarajan Thangavelu; Scott B Lovitch; Durga Bhavani Dandamudi; Caleph B Wilson; Benjamin G Vincent; Victor Tkachev; Jan M Pawlicki; Scott N Furlan; Leslie S Kean; Kazutoshi Aoyama; Patricia A Taylor; Angela Panoskaltsis-Mortari; Rocio Foncea; Parvathi Ranganathan; Steven M Devine; Joel S Burrill; Lili Guo; Catarina Sacristan; Nathaniel W Snyder; Ian A Blair; Michael C Milone; Michael L Dustin; James L Riley; David A Bernlohr; William J Murphy; Brian T Fife; David H Munn; Jeffrey S Miller; Jonathan S Serody; Gordon J Freeman; Arlene H Sharpe; Laurence A Turka; Bruce R Blazar
Journal:  J Clin Invest       Date:  2016-06-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.